$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Is fezolinetant available in Chinese pharmacies?
2026-02-01 22:25:32
Check Details
What is the quality of imported obeticholic acid? Is there any difference?
2026-02-01 22:25:32
Check Details
Why does neratinib/neratinib (He Li'an) need to be taken for one year?
2026-02-01 22:25:32
Check Details
Analysis of aprocitentan’s domestic launch time and registration approval status
2026-02-01 22:25:32
Check Details
Instructions for use and dosage of tilpotide/tilsiparatide (Mufenda) for weight loss and hypoglycemia
2026-02-01 22:25:32
Check Details
Analysis of the significance of skin rash with Pitobrutinib/Pitobrutinib (Zepali) targeted drugs
2026-02-01 22:25:32
Check Details
Talazoparib actual price reference table after medical insurance reimbursement
2026-02-01 22:25:32
Check Details
Summary of the effects, efficacy and clinical application of Crizotinib (Xalkori)
2026-02-01 22:25:32
Check Details
Whether aprocitentan is included in medical insurance and its reimbursement ratio and self-payment
2026-02-01 22:25:32
Check Details
Analysis of the target and physiological mechanism of action of tilpotide/tilsiparatide (Mufenda)
2026-02-01 22:25:32
Check Details
Analysis of whether the disease will relapse rapidly after discontinuation of Pitobrutinib/Pitobrutinib (Zepali)
2026-02-01 22:25:32
Check Details
Is the dosage form of Talazoparib (Tazena) capsules or other forms?
2026-02-01 22:25:32
Check Details
1
2
...
2383
2384
2385
2386
2387
2388
2389
...
10228
10229
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
2
Nintedanib: A Multi-Target Antifibrotic Agent for Slowing Pulmonary Fibrosis Progression
3
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
4
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
5
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
6
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
7
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
8
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
9
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
10
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations
11
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
12
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy